| Physiologically‐based pharmacokinetic‐led guidance for patients with cystic fibrosis taking elexacaftor‐tezacaftor‐ivacaftor with nirmatrelvir‐ritonavir for the treatment of … E Hong, LM Almond, PS Chung, AP Rao, PM Beringer Clinical Pharmacology & Therapeutics 111 (6), 1324-1333, 2022 | 19 | 2022 |
| Zika virus NS3 protease induces bone morphogenetic protein-dependent brain calcification in human fetuses W Chen, SS Foo, E Hong, C Wu, WS Lee, SA Lee, D Evseenko, ... Nature microbiology 6 (4), 455-466, 2021 | 17 | 2021 |
| Safety of elexacaftor/tezacaftor/ivacaftor dose reduction: Mechanistic exploration through physiologically based pharmacokinetic modeling and a clinical case series E Hong, R Li, A Shi, LM Almond, J Wang, AZ Khudari, S Haddad, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 43 (4 …, 2023 | 11 | 2023 |
| Application of physiologically based pharmacokinetic modeling to predict drug–drug interactions between elexacaftor/tezacaftor/ivacaftor and tacrolimus in lung transplant … E Hong, E Carmanov, A Shi, PS Chung, AP Rao, K Forrester, PM Beringer Pharmaceutics 15 (5), 1438, 2023 | 7 | 2023 |
| Glucosylceramide is essential for Heartland and Dabie bandavirus glycoprotein-induced membrane fusion T Xia, X Wu, E Hong, K Jung, CJ Lai, MJ Kwak, H Seo, S Kim, Z Jiang, ... PLoS Pathogens 19 (3), e1011232, 2023 | 7 | 2023 |
| Physiologically based pharmacokinetic modeling to guide management of drug interactions between elexacaftor-tezacaftor-ivacaftor and antibiotics for the treatment of … E Hong, LM Almond, PS Chung, AP Rao, PM Beringer Antimicrobial Agents and Chemotherapy 66 (11), e01104-22, 2022 | 7 | 2022 |
| PBPK-led guidance for cystic fibrosis patients taking elexacaftor-tezacaftor-ivacaftor with nirmatrelvir-ritonavir for the treatment of COVID-19 E Hong, LM Almond, PS Chung, AP Rao, PM Beringer medRxiv, 2022.01. 20.22269253, 2022 | 4 | 2022 |
| Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications E Hong, A Shi, P Beringer Expert Opinion on Drug Metabolism & Toxicology 19 (4), 203-216, 2023 | 1 | 2023 |
| Evaluation of the drug-drug interaction potential of rifabutin and elexacaftor/tezacaftor/ivacaftor using a physiologically based pharmacokinetic simulation approach E Hong, AP Rao, P Beringer PEDIATRIC PULMONOLOGY 55, S244-S244, 2020 | 1 | 2020 |
| Pharmacokinetic Enhancement of Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access E Hong, M Zampoli, PM Beringer Clinical Pharmacology & Therapeutics 115 (6), 1204-1207, 2024 | | 2024 |
| Preliminary evidence for sustained efficacy of CFTR modulator therapy with concomitant rifabutin administration E Hong, SM Parsons, L Sass, C Epstein, L Chan, C Brown, PH Eshaghian, ... Journal of Cystic Fibrosis 23 (3), 519-523, 2024 | | 2024 |
| Development of a cystic fibrosis population model for physiologically based pharmacokinetic models: Is it worth it? E Hong, PM Beringer CPT: Pharmacometrics & Systems Pharmacology 13 (4), 2024 | | 2024 |
| 423 Evaluation of the drug-drug interaction potential of elexacaftorrosuvastatin using a physiologically based pharmacokinetic simulation approach A Shi, P Beringer, E Hong, A Rao, P Chung Journal of Cystic Fibrosis 22, S221-S222, 2023 | | 2023 |
| 242: Evaluation of the drug-drug interaction potential of clofazimineivacaftor using a physiologically based pharmacokinetic simulation approach E Hong, A Rao, P Beringer Journal of Cystic Fibrosis 20, S117-S118, 2021 | | 2021 |
| Best regimen for elexacaftor/ivacaftor/tezacaftor with nirmatrelvir-ritonavir for COVID-19? E Hong Reactions 4 (2), 2022, 1900 | | 1900 |
